Long-acting formulations of heterocyclic GLP1 receptor agonists
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- EXAVIR THERAPEUTICS
- Filing Date
- 2025-12-19
- Publication Date
- 2026-06-25
AI Technical Summary
There is a need for improved formulations of small molecule heterocyclic GLP1 receptor agonists like orforglipron that enhance pharmacokinetic profile, peak-to-trough exposure, bioavailability, tolerability, and interval dosing, particularly for treating conditions such as type 2 diabetes, obesity, cardiovascular disease, and metabolic dysfunction-associated steatohepatitis (MASH).
Compositions comprising at least one therapeutic agent, such as orforglipron, combined with surfactants like polysorbate and poloxamer, and polymer additives like PEG and PLGA, formulated as extended-release formulations to improve delivery and efficacy.
The compositions provide sustained release of therapeutic agents, enhancing pharmacokinetic profiles and improving tolerability and efficacy for treating various diseases and disorders, including type 2 diabetes and obesity, over extended periods.
Smart Images
Figure US2025060685_25062026_PF_FP_ABST